vTv director granted 6,000 stock options at $35.08

vTv Therapeutics Inc. director Srinivas Akkaraju received a grant of stock options covering 6,000 shares of Class A common stock.

Rhea-AI Filing Summary

vTv Therapeutics Inc. director Srinivas Akkaraju received a grant of stock options covering 6,000 shares of Class A common stock. The options have an exercise price of $35.08 per share and expire on June 26, 2036. According to the terms, the award vests on the earlier of June 26, 2027 and the date of the 2027 annual general meeting of shareholders, provided he continues serving on the board. Following this grant, his total directly held option awards reported in this filing increased to 16,983 derivative securities.

Insider Trade Summary

Grant/Award: 6,000 shares

Grant/Award 1 txn

Insider AKKARAJU SRINIVAS

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director stock option (right to buy)	6,000	$35.08	$210K

Holdings After Transaction: Director stock option (right to buy) — 16,983 contracts (Direct)

Footnotes (1)

1. F1. The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.

Key Figures

Options granted: 6,000 options Exercise price: $35.08 per share Expiration date: June 26, 2036 +2 more

5 metrics

Options granted 6,000 options Director stock option grant on June 26, 2026

Exercise price $35.08 per share Strike price of director stock option grant

Expiration date June 26, 2036 Option term for director grant

Holdings after grant 16,983 derivative securities Total options held following this transaction

Vesting date trigger Earlier of June 26, 2027 or 2027 AGM Vesting condition for director stock options

Key Terms

Director stock option (right to buy), Class A Common Stock, exercise price, vests, +1 more

5 terms

Director stock option (right to buy) financial

"Director stock option (right to buy)"

Class A Common Stock financial

"underlying security title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

exercise price financial

"conversion or exercise price of $35.08 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests financial

"The option vests on the earlier of June 26, 2027, and the 2027 annual meeting"

annual general meeting of shareholders financial

"the date of the 2027 annual general meeting of shareholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did director Srinivas Akkaraju receive in this vTv Therapeutics (VTVT) Form 4 filing?

Director Srinivas Akkaraju received a grant of stock options covering 6,000 shares of vTv Therapeutics Class A common stock. These options are a compensation award, not an open-market share purchase or sale, and give him the right to buy shares at a fixed price.

What is the exercise price of the new vTv Therapeutics (VTVT) stock options?

The granted stock options have an exercise price of $35.08 per share. This means Akkaraju can buy each underlying share at $35.08 once the options vest, regardless of the market price at that time, until they expire.

When do Srinivas Akkaraju’s new vTv Therapeutics (VTVT) options vest?

The options vest on the earlier of June 26, 2027, and the date of vTv Therapeutics’ 2027 annual general meeting of shareholders. Vesting also requires that Akkaraju continue serving on the company’s board of directors through that vesting date.

When do the newly granted vTv Therapeutics (VTVT) stock options expire?

The granted stock options expire on June 26, 2036. After that expiration date, Akkaraju would no longer be able to exercise the options to purchase vTv Therapeutics Class A common stock at the fixed exercise price of $35.08 per share.

How many vTv Therapeutics (VTVT) derivative securities does Akkaraju hold after this grant?

After the stock option grant, Akkaraju is reported as directly holding 16,983 derivative securities. This total reflects his option holdings following the 6,000-share award and helps show the size of his reported option position with vTv Therapeutics.

Is this vTv Therapeutics (VTVT) Form 4 transaction an open-market trade?

No, this Form 4 shows a grant or award of director stock options rather than an open-market trade. The transaction is coded as an acquisition (code A), indicating compensation-related options, not a purchase or sale of existing vTv Therapeutics shares in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AKKARAJU SRINIVAS

(Last) (First) (Middle)

C/O VTV THERAPEUTICS INC.

3980 PREMIER DRIVE, SUITE 110

(Street)

HIGH POINT NORTH CAROLINA 27265

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
vTv Therapeutics Inc. [ VTVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director stock option (right to buy)	$35.08	06/26/2026		A		6,000		(1)	06/26/2036	Class A Common Stock	6,000	$35.08	16,983	D

Explanation of Responses:

1. The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.

Remarks:

	/s/ Elizabeth Keiley, as Attorney-in-fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)